HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ilia N Buhtoiarov Selected Research

tucotuzumab celmoleukin

12/2011Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.
8/2009Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ilia N Buhtoiarov Research Topics

Disease

12Neoplasms (Cancer)
11/2021 - 07/2004
4Neuroblastoma
12/2011 - 07/2004
3Necrosis
02/2011 - 06/2006
2Experimental Melanoma
03/2007 - 05/2005
1Non-Hodgkin Lymphoma (Lymphosarcoma)
02/2022
1Mucositis
02/2022
1Hodgkin Disease (Hodgkin's Disease)
01/2022
1Leukemia
05/2021
1Disseminated Intravascular Coagulation
05/2021
1Headache (Headaches)
05/2021
1Intracranial Hemorrhages (Intracranial Hemorrhage)
05/2021
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2021
1Ovarian Neoplasms (Ovarian Cancer)
12/2011
1Melanoma (Melanoma, Malignant)
12/2011
1Colonic Neoplasms (Colon Cancer)
08/2009
1Lymphoma (Lymphomas)
02/2009
1Sarcoma (Soft Tissue Sarcoma)
08/2008
1Mitochondrial Diseases (Mitochondrial Disease)
03/2007
1Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
06/2006
1Neoplasm Metastasis (Metastasis)
07/2004

Drug/Important Bio-Agent (IBA)

5Interleukin-2 (IL2)IBA
12/2011 - 07/2004
4CytokinesIBA
12/2011 - 06/2006
4Monoclonal AntibodiesIBA
08/2009 - 06/2006
3lorukafusp alfaIBA
12/2011 - 07/2004
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
03/2007 - 01/2006
2tucotuzumab celmoleukinIBA
12/2011 - 08/2009
2Interleukin-12 (IL 12)IBA
02/2011 - 01/2006
2Nitric Oxide (Nitrogen Monoxide)FDA Link
03/2007 - 06/2006
1Fibroblast Growth Factor 7FDA Link
02/2022
1GemcitabineFDA Link
01/2022
1Brentuximab VedotinIBA
01/2022
1Interleukin-15 (Interleukin 15)IBA
11/2021
1Dacarbazine (DIC)FDA LinkGeneric
05/2021
1pegaspargase (Oncaspar)FDA Link
01/2021
1Epithelial Cell Adhesion MoleculeIBA
12/2011
1Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA
12/2011
1Interleukin-2 Receptors (IL 2 Receptor)IBA
12/2011
1Actins (F Actin)IBA
12/2011
1Neoplasm Antigens (Tumor Antigens)IBA
12/2008
1OligodeoxyribonucleotidesIBA
03/2007
1TNF-Related Apoptosis-Inducing LigandIBA
03/2007
1Fas Ligand Protein (Fas Ligand)IBA
03/2007
1Interleukin-1alpha (Interleukin 1 alpha)IBA
03/2007
1LipopolysaccharidesIBA
06/2006

Therapy/Procedure

4Ligation
02/2009 - 05/2005
3Therapeutics
01/2022 - 07/2004
3Drug Therapy (Chemotherapy)
01/2022 - 06/2009
2Immunotherapy
11/2021 - 06/2006
1Salvage Therapy
01/2022
1Stem Cell Transplantation
01/2022
1Ambulatory Care (Outpatient Care)
05/2021
1Induction Chemotherapy
05/2021
1Radiofrequency Ablation
08/2009
1Aftercare (After-Treatment)
08/2009
1Transplantation
06/2009
1Intraperitoneal Injections
05/2005